🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Recurrent or Metastatic Solid Tumors

EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC NCT07617805Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EGFR/HER2 Dual-Target CAR-NK Cells, Fludarabine, Cyclophosphamide Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Immune Checkpoint Inhibitor Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial NCT04693468Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Axitinib, Crizotinib, Palbociclib Isethionate, Talazoparib Tosylate CT-95 in Advanced Cancers Associated With Mesothelin Expression NCT06756035Phase 19 sites📍 Denver📍 Chicago📍 Grand Rapids Context Therapeutics Inc. · Tests: CT-95 Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites📍 Tucson📍 New Haven📍 Baltimore Calico Life Sciences LLC · Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deat… Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors NCT06408688Phase 44 sites📍 Baden📍 Basel📍 Liestal University Hospital, Basel, Switzerland · Tests: Immune checkpoint inhibitors plus Iscador® Qu., Immune Checkpoint Inhibitors Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors NCT06320405Phase 1, Phase 21 site📍 Portland OHSU Knight Cancer Institute · Tests: Axatilimab, Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging ML-016 in Advanced Cancer With Lung and/or Liver Involvement NCT07723482Phase 1, Phase 23 sites📍 Miranda📍 Wollongong📍 Buderim BrYet US, Inc. · Tests: ML-016 A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors NCT06063681Phase 13 sites📍 Randwick📍 Clayton📍 Frankston Stingray Therapeutics · Tests: SR-8541A, Immune checkpoint inhibitor (ICI) Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Becotatug Vedotin Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors NCT05270213Phase 114 sites📍 Scottsdale📍 Tucson📍 Palo Alto Riboscience, LLC. · Tests: RBS2418, Pembrolizumab, Other approved anti-cancer therapy Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" NCT01365169NA1 site📍 Houston M.D. Anderson Cancer Center · Tests: Exercise Intervention, Health Telemonitoring, Health Telemonitoring, Health Telemonitoring, Health Telemonitoring Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors NCT07081984Phase 11 site📍 Shanghai Therorna · Tests: therapeutic tumor vaccine Combination of CAR-DC Vaccine and ICIs in Malignant Tumors NCT05631886Phase 11 site📍 Beijing Chinese PLA General Hospital · Tests: TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide, anti-PD-1 antibody, Anti-CTLA4 Monoclonal Antibody Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors NCT04064359Phase 127 sites📍 Phoenix📍 Los Angeles📍 Santa Monica Oxford BioTherapeutics Ltd · Tests: OBT076, a CD205-directed antibody-drug conjugate A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies NCT05803018Phase 1, Phase 21 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1 A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors NCT06469008Phase 11 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B16D1 SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors NCT07022002Phase 21 site📍 Hangzhou Shenyang Sunshine Pharmaceutical Co., LTD. · Tests: SSGJ-705, PD-1/L1 inhibitor combined with chemotherapy, SSGJ-705 combined with chemotherapy A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors NCT05464875n/a1 site📍 Guangzhou Xinhua Zhang, MD Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors NCT05533697Phase 1, Phase 239 sites📍 Los Angeles📍 San Francisco📍 Aurora ModernaTX, Inc. · Tests: mRNA-4359, Pembrolizumab, Ipilimumab, Nivolumab A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer NCT06184035Phase 1, Phase 22 sites📍 Adelaide📍 Melbourne Spago Nanomedical AB · Tests: [177Lu]Lu-SN201 Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells NCT06653777Phase 26 sites📍 Brest📍 Nice📍 Paris UNICANCER · Tests: Pemigatinib Study of ACR-2316 in Specific Advanced Solid Tumors NCT06667141Phase 1, Phase 215 sites📍 Phoenix📍 Beverly Hills📍 Newport Beach Acrivon Therapeutics · Tests: ACR-2316 Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer NCT01050504n/a1 site📍 Seattle University of Washington · Tests: Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer NCT05098210Phase 11 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography Test, Multigated Acquisition Scan A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors NCT05135975Phase 26 sites📍 Birmingham📍 Aurora📍 Washington D.C. Nationwide Children's Hospital · Tests: Cabozantinib Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic NCT07807345Phase 16 sites📍 Orlando📍 Boston📍 Oklahoma City Sutro Biopharma, Inc. · Tests: STRO-006, Pembrolizumab GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors NCT05430373Phase 15 sites📍 Beijing📍 Chongqing📍 Shanghai Grit Biotechnology · Tests: GT101 A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors NCT06952010Phase 111 sites📍 San Francisco📍 New Haven📍 Tampa Exelixis · Tests: XB628, Zanzalintinib A Phase I Open-Label, Single-Arm, Dose-Escalation Clinical and Pharmacology Study of CCI-001 as Monotherapy and in Combination With Standard Chemotherapy in Patients With Recurrent and/or Metastatic Solid Tumours NCT04823897Phase 11 site📍 Edmonton PharmaMatrix Holdings Ltd · Tests: CCI-001
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy